A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Completed · Phase 2 · Has a placebo group

Conditions studied: Severe Asthma

In brief

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.

Key facts

Study ID

NCT06196879

Run by

Upstream Bio Inc.

People needed

479

Starts

2024-02-27

Expected to finish

2026-03-19

Last updated by the study team

2026-05-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed, dated, and received a copy of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF).
• Age 18 to 80 years of age (inclusive) at the time of consent.
• Physician-diagnosed asthma for at least 12 months prior to Visit 1.
• Participant has evidence of bronchodilator (BD) reversibility as documented by either historical reversibility (within 12 months prior to study entry) or reversibility during screening.
• Documented treatment with a total daily dose of either medium or high dose inhaled corticosteroids (ICS) for at least 3 months. Participants on medium dose ICS must also have been taking at least one additional maintenance asthma controller medication for at least 3 months.
• Documented history of asthma exacerbation(s) within 12 months of Visit 1.
• Asthma Control Questionnaire-6 (ACQ-6) score greater than or equal to (>=) 1.5 at screening and randomization.
• Participant must have a pre-BD FEV1 value of >=30 percent (%) and <=80% predicted at Screening.
• Minimum compliance with daily diary and background asthma medication(s) as captured in the daily diary during the Run-in Period.
• Agrees to follow the required contraceptive techniques/methods.
• Female or male participant agrees not to donate eggs or sperm, respectively, for a period of 120 days after the last dose of the study drug intervention or at the Final Visit, whichever occurs last.

You may not qualify if…

• Inpatient hospitalization due to asthma at any time within 4 weeks prior to Visit 1 or during the Screening/Run-in Period.
• Previous exposure to verekitug (UPB-101) or known allergy/sensitivity to any of its excipients.
• Previous biologics, including those for asthma treatment, for which the appropriate washout period is not fulfilled prior to Visit 1. If the half-life is not known, a 24-week washout period prior to Visit 1 should be applied.
• Allergen immunotherapy (unless maintenance dose) within 12 weeks prior to Visit 1 or plans to begin therapy or change dosing during the study.
• For participants taking oral corticosteroids (OCS), the dose has not been stable for at least 2 weeks prior to Visit 1 and/or is >10 milligram (mg) daily, or >20 mg every other day.
• Evidence of active or suspected bacterial, viral, fungal, or parasitic infections within 2 weeks prior to Visit 1.
• History compatible with or diagnosis of a parasitic infection and has not been treated or has not responded to standard of care therapy.
• Current tobacco smokers, nicotine vapers (including electronic cigarettes), snuff users or participants with a smoking history >=10 pack years. (Former nicotine smokers with a smoking history of <10 pack years, former nicotine vapers and former snuff users must have stopped for at least 6 months prior to Visit 1 to be eligible).
• Positive coronavirus disease 2019 (COVID-19) test with lower respiratory tract symptoms within 28 days before Visit 1.
• Pregnant or breastfeeding or planning to become pregnant or breastfeed during the study or unwilling to use adequate birth control, if of reproductive potential and sexually active.

Where it is running

• Kern Research, Inc. — Bakersfield, California, United States
• Velocity Clinical Research - Lafayette LA — Los Angeles, California, United States
• Newport Native MD Inc — Newport Beach, California, United States
• California Medical Research Associates Inc. — Northridge, California, United States
• Integrated Research of Inland Inc — Upland, California, United States
• Allergy & Asthma Clinical Research — Walnut Creek, California, United States
• Allianz Research Institute — Westminster, California, United States
• Woodland Clinic Medical Group — Woodland, California, United States
• National Jewish Health — Denver, Colorado, United States
• Advance Pharma Research — Cutler Bay, Florida, United States
• Unique Clinical Trials — Doral, Florida, United States
• Health and Life Research Institute, LLC — Miami, Florida, United States
• Phoenix Medical Research — Miami, Florida, United States
• Research Institute of South Florida — Miami, Florida, United States
• Nouvelle Clinical Research — Miami, Florida, United States
• Anderson Allergy And Asthma, PA — Orlando, Florida, United States
• Edward Jenner Research Group, LLC — Plantation, Florida, United States
• R&B Medical Center — Tampa, Florida, United States
• Clinical Site Partners dba Flourish research — Winter Park, Florida, United States
• Clinical Site Partners, LLC dba Flourish Research — Winter Park, Florida, United States
• Pivotal Research Solutions — Stonecrest, Georgia, United States
• RNA America Health Sciences — Sugar Hill, Georgia, United States
• Treasure Valley Medical Research — Boise, Idaho, United States
• Velocity Clinical Research - Meridian — Meridian, Idaho, United States
• AllerVie Clinical Research — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.